"Ranolazine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An acetanilide and piperazine derivative that functions as a SODIUM CHANNEL BLOCKER and prevents the release of enzymes during MYOCARDIAL ISCHEMIA. It is used in the treatment of ANGINA PECTORIS.
| Descriptor ID |
D000069458
|
| MeSH Number(s) |
D02.065.199.092.850 D02.092.146.113.092.850 D03.383.606.841
|
| Concept/Terms |
Ranolazine- Ranolazine
- N-(2,6-dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-1-piperazineacetamide
- Renolazine
Ranolazine Hydrochloride- Ranolazine Hydrochloride
- Hydrochloride, Ranolazine
- Ranolazine Dihydrochloride
- Dihydrochloride, Ranolazine
- Ranolazine HCl
- HCl, Ranolazine
RS 43285- RS 43285
- 43285, RS
- RS-43285
- RS43285
|
Below are MeSH descriptors whose meaning is more general than "Ranolazine".
Below are MeSH descriptors whose meaning is more specific than "Ranolazine".
This graph shows the total number of publications written about "Ranolazine" by people in this website by year, and whether "Ranolazine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 0 | 1 | 1 |
| 2017 | 3 | 0 | 3 |
| 2018 | 5 | 1 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Ranolazine" by people in Profiles.
-
COVID-19-related arrhythmias and the possible effects of ranolazine. Med Hypotheses. 2021 Apr; 149:110545.
-
Ranolazine prevents pressure overload-induced cardiac hypertrophy and heart failure by restoring aberrant Na+ and Ca2+ handling. J Cell Physiol. 2019 07; 234(7):11587-11601.
-
Ranolazine Induced Delirium as a Rare Side Effect. Am J Ther. 2018 Nov/Dec; 25(6):e700-e701.
-
Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial. J Am Coll Cardiol. 2018 08 07; 72(6):636-645.
-
Ranolazine in Patients With Implantable Cardioverter-Defibrillators: Ready for Prime Time? J Am Coll Cardiol. 2018 08 07; 72(6):646-649.
-
Ranolazine treatment in the heterogeneous symptomatic stable coronary artery disease population. J Cardiovasc Med (Hagerstown). 2018 04; 19(4):186-190.
-
Efficacy of Ranolazine in Patients With Symptomatic Hypertrophic Cardiomyopathy: The RESTYLE-HCM Randomized, Double-Blind, Placebo-Controlled Study. Circ Heart Fail. 2018 01; 11(1):e004124.
-
[The RIVER-PCI study]. G Ital Cardiol (Rome). 2017 Oct; 18(10):677-681.
-
Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus: RIVER-PCI Trial. J Am Coll Cardiol. 2017 May 09; 69(18):2304-2313.
-
Ranolazine in Symptomatic Diabetic Patients Without Obstructive Coronary Artery Disease: Impact on Microvascular and Diastolic Function. J Am Heart Assoc. 2017 May 04; 6(5).